Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284259 | 0.85 | SCN9A (0.38) | KDM4ESCN9ASCN10A | |
| SCHEMBL8115428 | 0.78 | MAPK1 (0.40) | MAPK1SPRGPR119JAK2JAK1 | |
| SCHEMBL13705092 | 0.76 | PREP (0.36) | MAPK1SPRGPR119 | |
| SCHEMBL3130493 | 0.75 | GPR119 (0.40) | MAPK1GPR119JAK2JAK1 | |
| SCHEMBL13705098 | 0.75 | GPR119 (0.40) | MAPK1GPR119JAK2JAK1 | |
| SCHEMBL13705108 | 0.75 | IDH1 (0.46) | SCN9ASCN10AMAPK1GPR119 | |
| SCHEMBL26631302 | 0.75 | GPR119 (0.39) | KDM4EGPR119JAK2JAK1 | |
| SCHEMBL16696670 | 0.74 | NR1H2 (0.40) | KDM4EMAPK1 | |
| SCHEMBL16696671 | 0.74 | NR1H2 (0.40) | KDM4EMAPK1 | |
| SCHEMBL13705097 | 0.74 | IDO1 (0.38) | KDM4EMAPK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885SCN9A 1866/4885SCN10A 2828/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885SCN9A 1866/4885SCN10A 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.